Hermetica Superfood Encyclopedia
The Short Answer
Iron sodium citrate delivers ferrous iron (Fe²⁺) complexed with citrate that is absorbed via the duodenal divalent metal transporter 1 (DMT1), exploiting the superior intestinal uptake of the reduced ferrous state over ferric formulations. In a phase 3 non-inferiority trial of 180 iron-deficiency anemia patients, sodium ferrous citrate at 100 mg/day achieved target hemoglobin (≥12 g/dL) in 68% of women versus 62% for ferric citrate hydrate, while producing significantly less nausea (4% vs. 12%) and vomiting (2% vs. 8%).
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordiron sodium citrate benefits
Iron Sodium Citrate — botanical close-up
Health Benefits
**Iron Deficiency Anemia Correction**
Ferrous iron from iron sodium citrate is absorbed via DMT1 in the duodenum, efficiently replenishing hemoglobin; a phase 3 trial demonstrated target hemoglobin achievement in 68% of female IDA patients at 100 mg/day.
**Superior Gastrointestinal Tolerability**
The ferrous citrate complex exhibits markedly lower rates of nausea (4%) and vomiting (2%) compared to ferric citrate hydrate (12% and 8%, respectively), improving patient adherence to iron therapy.
**Serum Iron and Ferritin Restoration**
In iron-deficient hemodialysis patients, 3 months of supplementation raised mean serum iron from 37.4 to 94.6 µg/dL and ferritin from 37.6 to 87.0 ng/mL, demonstrating robust repletion of both circulating and stored iron pools.
**FGF23 Modulation in Chronic Kidney Disease**
Supplementation significantly reduced intact FGF23 from 1,820 to 1,240 pg/mL and C-terminal FGF23 from 309 to 259 pg/mL in hemodialysis patients, with reductions correlating directly with increases in ferritin, suggesting iron status drives FGF23 dysregulation.
**Reduction of Systemic Inflammation**
C-reactive protein levels decreased significantly (P < 0.01) in iron-deficient hemodialysis patients receiving oral iron sodium citrate for 3 months, indicating secondary anti-inflammatory effects mediated through improved iron homeostasis.
**Transferrin Saturation Improvement**
Treatment improved transferrin saturation (TSAT) to a mean of 38.8% in hemodialysis patients, restoring adequate iron transport capacity and reducing functional iron deficiency in a renally compromised population.
**Neutral Effect on Mineral Metabolism**
Unlike some phosphate-binding iron formulations, iron sodium citrate does not significantly alter serum phosphate, calcium, or intact parathyroid hormone levels, preserving bone and mineral metabolism integrity during supplementation.
Origin & History
Natural habitat
Iron sodium citrate is a synthetically manufactured pharmaceutical compound, not derived from a natural botanical source. It is produced through chemical complexation of ferrous iron (Fe²⁺) with citric acid and sodium, yielding a stable, water-soluble coordination compound with the molecular formula C₁₂H₁₀FeNa₄O₁₄. The compound was developed as a modern clinical formulation to optimize oral iron bioavailability and gastrointestinal tolerability, and is currently approved and manufactured in Japan under the trade name Ferromia® by Eisai Co.
“Iron sodium citrate is an entirely modern pharmaceutical compound with no documented history in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or Western herbalism. The compound was developed in the latter 20th and early 21st centuries as part of systematic efforts in pharmaceutical chemistry to improve upon the gastrointestinal side-effect profile and bioavailability limitations of earlier iron salts such as ferrous sulfate and ferric ammonium citrate. Its clinical development and regulatory approval occurred in Japan, where Eisai Co. brought Ferromia® to market, reflecting Japan's robust regulatory pathway for novel iron formulations in anemia and nephrology indications. There is no folk, ethnobotanical, or pre-modern cultural record associated with this compound, distinguishing it categorically from plant-derived or mineral-earth iron sources historically used in medicinal traditions.”Traditional Medicine
Scientific Research
The clinical evidence base for iron sodium citrate is small but of reasonable methodological quality within its studied indications, consisting primarily of one phase 3 non-inferiority randomized controlled trial (n=180 IDA patients) and one prospective observational study (n=31 iron-deficient hemodialysis patients), both conducted in Japan. The phase 3 RCT provides the strongest evidence, demonstrating non-inferiority and statistical superiority trends for hemoglobin response and gastrointestinal tolerability versus an active comparator (ferric citrate hydrate), with a comparative serum iron advantage of approximately 15% at 7 weeks. The hemodialysis study, while prospective, lacks a randomized control arm and is underpowered (n=31), and the authors explicitly call for larger RCTs to confirm FGF23 and inflammatory findings. Evidence is currently limited to Japanese clinical populations, with no large multinational trials, meta-analyses, or systematic reviews published on this specific formulation, warranting caution in broad generalization.
Preparation & Dosage
Traditional preparation
**Oral Tablet (Japan, Ferromia®)**
50 mg tablets; standard clinical trial dose is 100 mg/day (two tablets), taken orally for iron deficiency anemia treatment
**Liquid/Soluble Forms**
The compound's high water solubility makes it suitable for liquid formulation; specific commercial liquid preparations are not yet widely catalogued outside Japan.
**Iron Deficiency Anemia (Clinical Dose)**
100 mg elemental iron equivalent per day, as studied in phase 3 RCT; duration typically continued until hemoglobin target (≥12 g/dL women, ≥13 g/dL men) is achieved and iron stores are replete
**Hemodialysis/CKD Population**
100 mg/day equivalent) for a minimum of 3 months to achieve measurable improvements in ferritin and FGF23 modulation
Oral supplementation at low-dose regimens (study employed standard .
**Timing**
200–500 mg) is recommended to maintain the ferrous state and maximize DMT1-mediated absorption
Oral iron is generally best absorbed on an empty stomach or 30–60 minutes before meals; co-administration with ascorbic acid (vitamin C, .
**Standardization**
50 mg tablet formulation confirmed in Japanese approval)
Compound is defined by molecular formula C₁₂H₁₀FeNa₄O₁₄; pharmaceutical-grade preparations are standardized to defined iron content per tablet (.
Nutritional Profile
Iron sodium citrate contributes elemental iron as its primary nutritional constituent, delivered in the bioavailable ferrous (Fe²⁺) form; a 50 mg tablet provides a defined quantity of elemental iron calibrated to the molecular weight of the complex (C₁₂H₁₀FeNa₄O₁₄, MW ≈ 543.96 g/mol), yielding approximately 10.3% elemental iron by mass. The compound also delivers sodium and citrate as co-ligands; citrate is a tricarboxylic acid cycle intermediate that may offer minor alkalinizing effects but contributes negligible caloric or macronutrient value at supplemental doses. Bioavailability is enhanced relative to ferric formulations due to the pre-reduced Fe²⁺ state and the chelating effect of citrate, which maintains iron solubility across a range of intestinal pH environments; absorption efficiency is further modulated by body iron stores (regulated by hepcidin), concurrent dietary tannins, phytates, calcium, and antacids, which can inhibit uptake.
How It Works
Mechanism of Action
Iron sodium citrate delivers ferrous iron (Fe²⁺) to the intestinal brush border, where it is transported across the duodenal enterocyte apical membrane via divalent metal transporter 1 (DMT1), the primary high-affinity intestinal iron importer; the ferrous oxidation state is critical because DMT1 transports only Fe²⁺, and the citrate ligand stabilizes this reduced form during gastric transit. Once absorbed, iron enters the body's labile iron pool, replenishing transferrin-bound serum iron and hepatic ferritin stores, which in turn modulates the hepatic hormone hepcidin—the master regulator of systemic iron homeostasis—and downstream iron export via ferroportin on enterocytes and macrophages. In chronic kidney disease, improved iron stores appear to suppress erythropoietic and hypoxic signaling in osteocytes and bone marrow, leading to reduced transcription and secretion of FGF23, a phosphaturic hormone whose elevation is independently associated with cardiovascular mortality in hemodialysis patients. Ascorbic acid co-administration further enhances bioavailability by chemically reducing any Fe³⁺ back to Fe²⁺ in the intestinal lumen, maintaining substrate compatibility with DMT1 and increasing net absorption efficiency.
Clinical Evidence
The pivotal phase 3 non-inferiority trial enrolled 180 iron-deficiency anemia patients randomized to sodium ferrous citrate 100 mg/day or ferric citrate hydrate 500–1,000 mg/day, with the primary endpoint of hemoglobin target achievement (≥12 g/dL for women); sodium ferrous citrate met non-inferiority criteria and numerically outperformed on both efficacy (68% vs. 62%) and gastrointestinal adverse events. A separate 3-month prospective study in 31 iron-deficient maintenance hemodialysis patients demonstrated statistically significant improvements in serum iron (P < 0.0001), ferritin (P < 0.01), FGF23 (P < 0.05), and CRP (P < 0.01), with no adverse impact on phosphate, calcium, or parathyroid hormone. Effect sizes were clinically meaningful—serum iron more than doubled and intact FGF23 declined by approximately 32%—but the small sample size and absence of a concurrent control group limit causal inference for the CKD population. Overall confidence in the IDA indication is moderate-to-good based on RCT data; confidence in the CKD/FGF23 indication remains preliminary pending larger controlled trials.
Safety & Interactions
At the clinically studied dose of 100 mg/day, iron sodium citrate demonstrates a favorable safety profile with nausea occurring in approximately 4% and vomiting in 2% of IDA patients; these rates are significantly lower than comparator ferric iron formulations and represent its primary tolerability advantage. Iron supplementation as a class carries risk of iron overload (hemosiderosis) in patients with hereditary hemochromatosis, hemolytic anemias, or those receiving concurrent parenteral iron, and supplementation should be guided by serum ferritin and transferrin saturation monitoring. Drug interactions relevant to oral iron include reduced absorption of fluoroquinolone and tetracycline antibiotics, levothyroxine, bisphosphonates, levodopa, and methyldopa when co-administered; a minimum 2-hour separation is standard practice. Pregnancy and lactation use should follow prescribing physician guidance, as iron requirements are elevated in pregnancy but excess iron supplementation carries theoretical oxidative risks; specific safety data for iron sodium citrate in pregnant populations have not been reported in the available literature.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Sodium ferrous citrateFerromia®C₁₂H₁₀FeNa₄O₁₄Iron(II) sodium citrateFerrous sodium citrate
Frequently Asked Questions
What is iron sodium citrate used for?
Iron sodium citrate is used primarily to treat iron deficiency anemia and iron deficiency in patients with chronic kidney disease, including those on hemodialysis. It delivers ferrous iron (Fe²⁺) complexed with citrate, which is absorbed via the divalent metal transporter 1 (DMT1) in the duodenum to replenish hemoglobin, serum iron, and ferritin stores. In Japan, it is approved under the brand name Ferromia® at a standard clinical dose of 100 mg/day.
How does iron sodium citrate differ from ferrous sulfate or ferric iron supplements?
Iron sodium citrate provides iron pre-reduced in the ferrous (Fe²⁺) state complexed with citrate, which maintains solubility across varying intestinal pH levels and directly matches the Fe²⁺ substrate requirement of the DMT1 transporter, potentially improving absorption efficiency over ferric (Fe³⁺) formulations that require reduction before uptake. In a phase 3 clinical trial, sodium ferrous citrate produced approximately 15% higher serum iron concentrations than ferric citrate hydrate after 7 weeks, along with significantly lower rates of nausea (4% vs. 12%) and vomiting (2% vs. 8%), indicating superior tolerability. Ferrous sulfate, while effective and inexpensive, is associated with higher gastrointestinal side-effect rates compared to iron sodium citrate in comparative data.
What is the recommended dosage of iron sodium citrate?
The dosage employed in the pivotal phase 3 clinical trial for iron deficiency anemia is 100 mg/day, typically delivered as two 50 mg tablets orally, which is the formulation approved in Japan (Ferromia®). Supplementation is generally continued until hemoglobin targets (≥12 g/dL in women, ≥13 g/dL in men) are achieved and iron stores (serum ferritin) are adequately replenished. Co-administration with 200–500 mg of ascorbic acid on an empty stomach is recommended to maintain the ferrous state and optimize DMT1-mediated absorption.
Is iron sodium citrate safe for people with chronic kidney disease or on dialysis?
A 3-month prospective study in 31 iron-deficient hemodialysis patients found that oral iron sodium citrate supplementation significantly improved serum iron, ferritin, and transferrin saturation without adversely affecting serum phosphate, calcium, parathyroid hormone, infection risk, or albumin levels. The compound also reduced intact FGF23 levels by approximately 32% and decreased C-reactive protein, suggesting benefits beyond iron repletion including reduced cardiovascular risk markers in CKD. However, the evidence is limited to one small uncontrolled study, and larger randomized controlled trials are needed before broad clinical recommendations can be made for this population.
Does iron sodium citrate interact with any medications?
As an oral iron supplement, iron sodium citrate shares the drug interaction profile common to ferrous iron formulations; it can significantly reduce the absorption of fluoroquinolone and tetracycline antibiotics, levothyroxine, bisphosphonates, levodopa, and methyldopa when taken concurrently, and a minimum 2-hour separation between iron and these medications is standard clinical guidance. Antacids and proton pump inhibitors may raise intestinal pH and reduce ferrous iron solubility, potentially impairing absorption. Concurrent use with parenteral iron or in patients with conditions predisposing to iron overload (hereditary hemochromatosis, thalassemia) requires careful monitoring of ferritin and transferrin saturation to avoid iron toxicity.
What makes iron sodium citrate easier on the stomach compared to other iron supplements?
Iron sodium citrate forms a stable ferrous citrate complex that reduces gastrointestinal irritation by minimizing direct contact between ferrous iron and the intestinal lining. Clinical data shows nausea rates of only 4% and vomiting rates of 2% with iron sodium citrate, substantially lower than traditional ferrous sulfate formulations. This improved tolerability is attributed to the citrate chelation, which also enhances absorption efficiency while buffering stomach acid effects.
Who should consider iron sodium citrate supplementation instead of dietary iron sources alone?
Iron sodium citrate is particularly beneficial for patients with iron deficiency anemia (IDA) who cannot achieve adequate hemoglobin levels through diet alone, including those with malabsorption disorders, heavy menstrual bleeding, or chronic blood loss. Phase 3 clinical trials demonstrated that 68% of female IDA patients achieved target hemoglobin levels at 100 mg/day dosing. Individuals intolerant to other iron formulations due to GI side effects are also ideal candidates for iron sodium citrate's gentler formulation.
How does the citrate component in iron sodium citrate affect iron absorption in the body?
The citrate ligand stabilizes ferrous iron in a chelated complex that maintains optimal pH for absorption in the duodenum while facilitating transport via the divalent metal transporter 1 (DMT1). This chelation prevents iron from precipitating at higher pH levels in the small intestine, which would otherwise reduce bioavailability. The citrate complex essentially acts as a "delivery vehicle" that enhances iron uptake efficiency compared to non-chelated ferrous salts.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w iron-sodium-citrate curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
